Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. Read my analysis on RXRX here.
Samsung’s AI lab in Montreal new Tiny Recursive Model with only 7M parameters performs as well, if not better in some instances, than systems much larger.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback